Nash Clinical Trial - Psoriasis & Non Alcoholic Steatohepatitis: Is There

Status Not yet recruiting

Clinical Trial Summary

The study is to assess frequency of NASH in Psoriatic patient and to measure the level of proinflammatory cytokines including TNFα, interleukin (IL)-6 and IL-17 and anti-inflammatory cytokines including IL10, IL35 by ELISA.

Clinical Trial Description

• Psoriasis is a chronic proliferative and inflammatory condition of the skin. It is characterized by erythematous plaques covered with silvery scales, particularly over the extensor surfaces, scalp, and lumbosacral region. The disorder can also affect the joints and eyes. Psoriasis has no cure and the disease waxes and wanes with flareups. There are several subtypes of psoriasis but the plaque type is the most common and presents on the trunk, extremities, and scalp. Psoriasis has a prevalence ranging from 0.2% to 4.8%. In parallel, nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide, affecting an estimated 30% of the adult population in developed countries. NAFLD and the metabolic syndrome are mutually and bi-directionally associated, as these two pathologic condition share insulin resistance as a common pathophysiological mechanism. NAFLD encompasses a spectrum of pathologic conditions ranging from simple steatosis to nonalcoholic steatohepatitis((NASH) featuring steatosis associated with inflammatory changes, hepatocellular ballooning and pericellular fibrosis), to advanced fibrosis and cirrhosis. NAFLD is projected to become the most common indication for liver transplantation in the United States by 2030 . Over the last few years, multiple studies have demonstrated that psoriasis is associated with NAFLD. The majority reported a prevalence of around 50 % (range 14.4 % to 65.5 %) for NAFLD in psoriatic patients. The contribution of IL-17 to the pathogenesis of both psoriasis and NAFLD is intriguing. Th17 cells can be detected in fat tissue and IL-17 itself regulates glucose metabolism and adipogenesis. Likewise, IL-17(A)-secreting Th17 cells may promote the progression from simple steatosis to steatohepatitis [10] Therefore, both psoriasis and NAFLD pathogenesis seem to be linked to the joint proinflammatory Th17 axis (and other cytokines such as TNFα and IL-6). ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Nash
Non-alcoholic Fatty Liver Disease
Psoriasis

Clinical Trial Details

NCT number	NCT05994677
Study type	Observational
Source	Assiut University
Contact
Status	Not yet recruiting
Phase
Start date	August 2023
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Completed	`NCT02923154` - Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)	Phase 2
Withdrawn	`NCT03980912` - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
Terminated	`NCT04565717` - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 1
Recruiting	`NCT04302051` - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting	`NCT05327127` - Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis	Phase 2
Completed	`NCT06348706` - Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes	Phase 3
Recruiting	`NCT05935488` - Early Liver Disease Breath Detection
Active, not recruiting	`NCT06315361` - DIAbetes and NAFLD
Completed	`NCT03187496` - Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.	Phase 1
Recruiting	`NCT04442334` - The European NAFLD Registry
Recruiting	`NCT06338969` - The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis	N/A
Completed	`NCT05193916` - A Phase II Clinical Trial of Chiglitazar for NASH	Phase 2
Active, not recruiting	`NCT05669677` - Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Not yet recruiting	`NCT04783116` - Plant Stanols and Liver Inflammation in Overweight and Obese Children	N/A
Recruiting	`NCT06193629` - A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar	N/A
Completed	`NCT04006145` - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH	Phase 2
Recruiting	`NCT04232293` - Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus	N/A
Recruiting	`NCT06410924` - A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Psoriasis and Non Alcoholic Steatohepatitis: Is There a Shared Inflammatory Network ? — PANASH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms